LL-37 fragment KR-12

General Information


DRACP ID  DRACP00813

Peptide Name   LL-37 fragment KR-12

Sequence  KRIVQRIKDFLR

Sequence Length  12

UniProt ID  Not available

PubChem CID  Not available

Origin  Synthetic

Type  Synthetic peptide

Classification

  

Active ACP Membrane-targeted



Activity Information


Cell Line Disease Cancer Classified Activity Assay Testing Time Literature
U-937/GTB Adult acute monocytic leukemia; Acute monoblastic/monocytic leukemia Leukemia 15% Killing=100 µM FDA cytotoxicity assay 72h 1

Hemolytic Activity  Human erythrocytes: 50% Hemolysis>80 µM

Normal (non-cancerous) Cytotoxicity  CEM-SS cells: 50% cell death >63.5 µM

Target  Not available

Affinity  Not available

Mechanism  Not available

Nature  Anticancer; Antibacterial; Antifungal; Antiviral



Structure Information


PDB ID  Not available

Predicted Structure  DRACP00813

Helicity  Not available

Linear/Cyclic  Linear

Disulfide/Other Bond  Not available

N-terminal Modification  Free

C-terminal Modification  Free

Other Modification  None

Chiral  L



Physicochemical Information


Formula  C71H126N24O16

Absent amino acids  ACEGHMNPSTWY

Common amino acids  R

Mass  176832

Pl  12.24

Basic residues  5

Acidic residues  1

Hydrophobic residues  5

Net charge  4

Boman Index  -4834

Hydrophobicity  -70.83

Aliphatic Index  121.67

Half Life 
  Mammalian: 1.1 hour
  Yeast: 3 min
  E.coli: 2 min

Extinction Coefficient cystines  0

Absorbance 280nm  0

Polar residues  0

Amino acid distribution



Literature Information


Literature 1

Pubmed ID 29430821

Title  Alanine and Lysine Scans of the LL-37-Derived Peptide Fragment KR-12 Reveal Key Residues for Antimicrobial Activity

Doi 10.1002/cbic.201700599

Year  2018

Literature 2

Pubmed ID 18591279

Title  Anti-human immunodeficiency virus type 1 activities of antimicrobial peptides derived from human and bovine cathelicidins

Doi 10.1128/AAC.00452-08

Year  2008

Literature 3

Pubmed ID 32153522

Title  Backbone Cyclization and Dimerization of LL-37-Derived Peptides Enhance Antimicrobial Activity and Proteolytic Stability

Doi 10.3389/fmicb.2020.00168

Year  2020

Patent

Patent ID Not available

Patent Title  Not available

Other Iinformation  Not available

Other Published ID  Not available




DRACP is developed by Dr.Zheng's team.